Inactivated L. paracasei LPC1114 for gum health
SynbiOFF® LPc is a postbiotic ingredient utilizing inactivated L. paracasei LPC1114 to enhance gum health. It offers regenerative, anti-inflammatory, and antioxidant benefits, and aims to prevent dysbiosis-associated gingivitis. Clinical validation is planned to confirm its efficacy.
Overview
SynbiOFF® LPc is an innovative postbiotic ingredient formulated with inactivated L. paracasei LPC1114, specifically designed to promote gum health. It offers a targeted approach to managing gingivitis by leveraging the biological activity of heat-inactivated bacterial cells. This solution stands out for its ability to enhance wound closure, increase collagen deposition, and balance extracellular matrix remodeling in human gingival fibroblasts. SynbiOFF® LPc also exhibits significant anti-inflammatory and antioxidant effects, making it a promising alternative to existing treatments like hyaluronic acid.
Technical specifications
- Pro-regenerative effects: Enhances wound healing and collagen production.
- Anti-inflammatory activity: Demonstrated reduction in pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in THP-1-derived M1 macrophages.
- Antioxidant properties: Increased expression of superoxide dismutase (SOD) and reduced reactive oxygen species (ROS) production.
- Versatile formulation: Suitable for various oral care products, including toothpaste, mouthwash, and topical gels.
- Microbiome-friendly: Supports oral health without disrupting the resident microbiome.
Technology readiness level
Currently at Technology Readiness Level 5, SynbiOFF® LPc has undergone extensive in vitro testing, demonstrating its potential benefits in oral health formulations. Future validation includes a two-phase clinical trial process to confirm its effectiveness in managing gingivitis. The first phase focuses on formulation stability and compatibility, while the second phase involves a controlled clinical trial to assess efficacy. The project seeks partnership for clinical access, analytics, and regulatory support in both the EU and US markets.
About SynBalance
SynBalance is an Italian biotechnology company and spin-off of ROELMI HPC, specialized in the design, development, and manufacture of high-quality, clinically tested probiotic strains and related microbiome solutions. Operating within the nutraceutical industry, the company utilizes advanced bio-fermentation technology to create proprietary strains of Lactobacilli, Bifidobacteria, and other species. Their R&D process incorporates in-vitro and ex-vivo screening alongside human clinical trials to ensure scientific efficacy, focusing on functional areas such as intestinal health, the gut-skin axis, cardiometabolic risk, immune modulation, and mental health. The company also offers inactivated bacterial strains, known as postbiotics, to expand compatibility with various active ingredients.
Serving both small and multinational partners, SynBalance provides a versatile service model that includes raw material supply, branded and tailor-made formulations, white-label production, and licensing of ready-to-go product concepts. By providing comprehensive product dossiers and regulatory support, the company enables its partners to accelerate time-to-market and develop personalized, evidence-based health strategies. Their business is supported by an integrated management system compliant with international standards, emphasizing quality, safety, and a commitment to modulating the human microbiota to support long-term health and wellness.
delivered to your inbox.